Zhongda Hospital, Affiliated to Southeast University
Nanjing, Jiangsu, China
Location status: Recruiting
Location contact
Yingzi Huang
CONTACT
NCT Number: NCT06514209
Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse alveolar injury caused by a variety of pulmonary and extrapulmonary factors, leading to refractory hypoxemia. It has high incidence and mortality rates. Neuromuscular blocking agents (NMBAs) play a crucial role as adjunctive therapy for ARDS, aiding in lung-protective ventilation by inhibiting excessive spontaneous breathing, improving patient-ventilator synchrony, and reducing barotrauma.
Determining the appropriate depth of muscle relaxation in moderate to severe ARDS patients receiving NMBAs remains a clinical challenge. Research has shown that partial neuromuscular blockade is feasible in certain ARDS patients. However, large randomized controlled trials (RCTs) and clinical practices often use higher doses of NMBAs to ensure complete cessation of spontaneous breathing. This indicates an ongoing debate regarding the optimal depth of neuromuscular blockade necessary for lung-protective ventilation in ARDS patients. It also raises the question of whether the optimal depth of neuromuscular blockade varies among patients with different severities of ARDS.
This study aims to investigate changes in respiratory mechanics and other physiological parameters in moderate to severe ARDS patients under different depths of neuromuscular blockade. The investigators will evaluate the impact of targeted neuromuscular blockade depth on lung protection in these patients.
Interested in participating?
Request Info18 day–85 year
All sexes
Interventional
Not applicable
Nanjing, Jiangsu, China
Location status: Recruiting
Yingzi Huang
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient's spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
Time frame: At baseline and 15 minutes after each adjustment of the cisatracurium dose.
Time frame: At baseline and 15 minutes after each adjustment of the cisatracurium dose.
Time frame: At baseline and 15 minutes after each adjustment of the cisatracurium dose.
Contact information is provided by the study sponsor or research team.
Southeast University, China
Other
Acronym: ARDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06701682
ARDS, ARDS (Acute Respiratory Distress Syndrome)
Birmingham, Alabama, United States
View Trial DetailsNCT06701669
ARDS, ARDS (Acute Respiratory Distress Syndrome)
Birmingham, Alabama, United States
View Trial DetailsNCT06703073
ARDS, ARDS (Acute Respiratory Distress Syndrome)
Birmingham, Alabama, United States
View Trial DetailsNCT06701656
ARDS, ARDS (Acute Respiratory Distress Syndrome)
Birmingham, Alabama, United States
View Trial Details